Figure 6 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

CAR27/IL-15 NK cells improve tumor control in a MM.1S TNFRSF17 KO mouse model. A, Mice were first injected with MM.1S TNFRSF17 KO tumor cells on day −3. The mice were subsequently treated (day 0) with no additional cells (tumor alone), NT NK, CAR27/IL-15 NK, CAR27 NK, and IL-15 NK cells. B, BLI was obtained weekly until day 54. Different radiance scales were used for early (days 0–14) and late imaging due to signal intensities spanning several orders of magnitude. An ‘X’ denotes that all mice in the group have died. C, BLI signal for individual mice plotted over days post-CAR NK cell treatment. D, Percentage of human CD45+ cells (NK cells) detected in the blood at day 12 after NK cell infusion. Only three of the five mice per group were bled for this analysis. E, Kaplan–Meier survival plot. Blue asterisks: NT NK vs. CAR27/IL-15 NK; green asterisk: CAR27 NK vs. CAR27/IL-15 NK; and magenta asterisk: IL-15 NK vs. CAR27/IL-15 NK. F, Weight of the mice over time. Data are represented as mean ± SD. P values were calculated using the log-rank test (E). *, P ≤ 0.05; **, P ≤ 0.01.